Navigation Links
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
Date:5/6/2009

or efficacy measures when compared to a bare-metal stent in patients with AMI, while demonstrating a comparable safety profile," said Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital and Principal Investigator of the trial.

"This is the first prospective, global randomized clinical trial sufficiently powered to provide conclusive data comparing DES and BMS in heart attack patients," continued Dr. Stone. "The findings from the HORIZONS AMI trial should have a major impact on how decisions are made regarding the use of drug-eluting stents in these high-risk patients during the early hours of a heart attack. This study provides much needed data, and the patients in this trial will be followed for five years to determine if these favorable results are maintained."

"Boston Scientific is proud to support this and other large clinical trials that provide the medical community with relevant data that can be used in combination with broader clinical judgment to develop optimal treatment strategies for challenging patient subsets," said Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "The HORIZONS AMI trial provides valuable insight into the benefits of the TAXUS paclitaxel-eluting stent compared to bare-metal stents, in this important high-risk AMI patient population."

One-year results from the HORIZONS AMI trial showed ischemia-driven TLR was reduced by 41 percent with DES compared to BMS (4.5% vs. 7.5%, p=0.002), with parallel reduction in ischemia-driven target vessel revascularization (TVR) among patients treated with DES (5.8% vs. 8.7%, p=0.006). Angiographic follow-up at 13 months was available for 910 DES patients (1,081 lesions) and 293 BMS patients (332 lesions), and showed a 56 percent reduction in the secon
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... schizophrenia twice as likely to have children with the ... News) -- Parents of children with autism have double ... condition than parents of children without autism, according to ... the information may provide a way for experts to ...
... its Kind in the U.S. to Address Epidemic Drug & Alcohol Use, by Suburban Teens; Integrates Academics, Intervention, ... Hope; Teens to Share Personal Stories, MENDHAM, N.J., May 5 , WHAT: ... next ... nation,s only fully-licensed coeducational special ed ...
... Club Members Share Life-Changing Experiences, SAN RAMON, ... largest,national fitness club chain, today launched an innovative ... overcome personal challenges,through fitness. The "12 Million Lives" ... a life-changing journey by using the power of ...
... announced plans to,align their Ophthalmic Strategic Business Unit (Lumenis ... the highest standards of,quality and reliability., Lumenis, Ophthalmic ... who will lead the unit for the present time ... for Business Development, and,will replace Mr. Jake Vander Zanden, ...
... enrolling in the state childrens health insurance program (SCHIP) ... would further prolong these childrens need to address asthma ... which happens when patients switch to SCHIP when they ... waiting periods to qualify for SCHIP. Waiting periods ...
... LABAs ARE SAFE AND EFFECTIVE FOR COPD , ... (LABA) to increased risk for adverse events or respiratory-related ... obstructive pulmonary disease (COPD); however, a recent article shows ... metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the ...
Cached Medicine News:Health News:Autistic Kids More Likely to Have Parents With Mental Illness 2Health News:Daytop - NJ to Dedicate New Preparatory School This Week 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 3Health News:Lumenis Announces changes in Lumenis Vision Strategic Business Unit 2Health News:New SCHIP enrollees have unmet health care needs 2Health News:News briefs: May issue of the journal Chest 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: